A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides
The Nix-TB clinical trial evaluated a new 6 month regimen containing three oral drugs;
bedaquiline (B), pretomanid (Pa), and linezolid (L)(BPaL regimen) for the treatment of …
bedaquiline (B), pretomanid (Pa), and linezolid (L)(BPaL regimen) for the treatment of …
Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis
AA Bauman, JP Sarathy, F Kaya… - Antimicrobial Agents …, 2024 - journals.asm.org
The spectinamides are novel, narrow-spectrum semisynthetic analogs of spectinomycin,
modified to avoid intrinsic efflux by Mycobacterium tuberculosis. Spectinamides, including …
modified to avoid intrinsic efflux by Mycobacterium tuberculosis. Spectinamides, including …
Preclinical evaluation of inhalational spectinamide-1599 therapy against tuberculosis
The lengthy treatment time for tuberculosis (TB) is a primary cause for the emergence of
multidrug resistant tuberculosis (MDR-TB). One approach to improve TB therapy is to …
multidrug resistant tuberculosis (MDR-TB). One approach to improve TB therapy is to …
Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant Mycobacterium tuberculosis
Tuberculosis (TB) is a leading global cause of mortality owing to an infectious agent,
accounting for almost one-third of antimicrobial resistance (AMR) deaths annually. We …
accounting for almost one-third of antimicrobial resistance (AMR) deaths annually. We …
Development and characterization of a dry powder formulation for anti-tuberculosis drug spectinamide 1599
Purpose Human tuberculosis (TB) is a global health problem that causes nearly 2 million
deaths per year. Anti-TB therapy exists, but it needs to be administered as a cocktail of …
deaths per year. Anti-TB therapy exists, but it needs to be administered as a cocktail of …
Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics
Spectinamides 1599 and 1810 are lead spectinamide compounds currently under
preclinical development to treat multidrug-resistant (MDR) and extensively drug-resistant …
preclinical development to treat multidrug-resistant (MDR) and extensively drug-resistant …
Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes
ZH Temrikar, S Kodidela, S Kumar, J Liu, GT Robertson… - Tuberculosis, 2023 - Elsevier
Spectinamides are a novel series of spectinomycin analogs being developed for the
treatment of tuberculosis. The preclinical lead spectinamide 1599 is an antituberculosis drug …
treatment of tuberculosis. The preclinical lead spectinamide 1599 is an antituberculosis drug …
Model-based exposure-response assessment for spectinamide 1810 in a mouse model of tuberculosis
Despite decades of research, tuberculosis remains a leading cause of death from a single
infectious agent. Spectinamides are a promising novel class of antituberculosis agents, and …
infectious agent. Spectinamides are a promising novel class of antituberculosis agents, and …
[HTML][HTML] Enhancing the therapeutic window for Spectinamide anti-tuberculosis Agents: Synthesis, Evaluation, and activation of phosphate prodrug 3408
Spectinamides are a novel class of narrow-spectrum antitubercular agents with the potential
to treat drug-resistant tuberculosis infections. Spectinamide 1810 has shown a good safety …
to treat drug-resistant tuberculosis infections. Spectinamide 1810 has shown a good safety …
[图书][B] Model-Based Dose-Exposure-Response Assessment for Lead and Backup Spectinamide in a Mouse Model of Tuberculosis
SJ Wagh - 2020 - search.proquest.com
Despite decades of research, tuberculosis remains the oldest pathogen-based disease that
is the leading cause of death from a single infectious agent. Among many anti-tubercular …
is the leading cause of death from a single infectious agent. Among many anti-tubercular …